Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anluohuaxian Pill and Entecavir for Reversing HBV-Related Liver Fibrosis
NCT03568578Unknown
- Sponsor
- Peking University First Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Trial of anluohuaxian in Liver Fibrosis (LF) and Liver cirrhosis (LC) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Construct a non-invasive model based on laboratory tests. Status: unknown.
02
Drugs
anluohuaxian
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03568578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568578.